Cód. SSPA: IBiS-DS-32
“Endocrinology, Diabetes and Clinical Nutrition” (EDN-HUVM) research group comprises a multidisciplinary team focused on clinical investigation in endocrinology and metabolic diseases and especially in Diabetes and its complications. Our areas of interests are related to minimally invasive techniques applied to thyroid disease, thyroid orbitopathy, paraganglioma-pheochromocytoma syndromes and adrenal diseases and clinical nutrition in oncology.
Regarding diabetes research, the team has extensive experience in national and european competitive research projects, in phase II and phase III clinical trials related to disease-modifying therapies (DMT) and applied technologies (insulin pumps, glucose monitoring devices and hybrid closed-loop systems). Likewise, our team is currently participating in DMT clinical trials in type 1 Diabetes in early phases being a national reference center in both studies for its recruiting capacity and quality of execution.
Through its principal investigator, since 2024, EDN-HUVM is a full member of INNODIA network. At the moment we lead 3 competitive national projects in the area of diabetes and we coordinate the largest, national multicenter study aimed at studying the causal factors of hypoglycemia in adults with T1D.
We are committed to the impulse of translational research in Diabetes and collaborate as clinical group within a collaboration agreement with CABIMER and in research projects financed by the Ministry of Health and Consumption and by Breakthrough T1D (former Juvenile Diabetes Research Foundation). Likewise, its PI coordinates regional participation in the European Joint Action Care4Diabetes.
- Research Lines
1. Diabetes Line
◦ Morbidity and mortality and epidemiological analysis of health outcomes in the context of the Public Health System of Andalusia.
◦ Microvascular and macrovascular complications of diabetes.
◦ Mental health assessment in patients with diabetes.
◦ Evaluation of the clinical impact of psycho-emotional intervention in patients with diabetes.
◦ Neurocognitive assessment in patients with diabetes.
◦ Clinical and economic evaluation of the application of diabetes-related technologies.
◦ Clinical and economic evaluation of telemedicine in the care of diabetes patients.
◦ Effectiveness and safety of new drugs in diabetes.
◦ Implementation and evaluation of the impact of hospital insulinization protocols.
2. Thyroid Pathology Line
◦ Optimization of diagnostic capacity in thyroid pathology.
◦ Effectiveness of interventional ultrasound in the treatment of nodular thyroid pathology.
◦ Ultrasound factors predicting malignancy in nodular thyroid pathology.
◦ Epidemiology and predictors of health outcomes in thyroid cancer.
◦ Clinical effectiveness of the multidisciplinary approach to thyroid orbitopathy.
3. Hypothalamic-Pituitary Pathology Line
◦ Prognostic markers in pituitary tumors.
◦ Clinical factors predicting response to pharmacological treatment in functioning pituitary tumors.
◦ Morbidity and mortality associated with pituitary tumors.
4. Obesity and Clinical Nutrition Line
◦ Effectiveness of bariatric surgery in the treatment of obesity and its impact on nutritional status and comorbidities.
◦ Effects of new drugs and their combinations in the treatment of obesity and their effects.
◦ Usefulness of morphofunctional assessment in the management of disease-related malnutrition.
◦ Effectiveness of nutritional support in the morbidity and mortality of cancer patients.
5. Care and Therapeutic Education Line
◦ Impact of group therapeutic education on the quality of life of people with chronic diseases.
◦ Educational interventions in the management of fear of hypoglycemia.
◦ Health outcomes of nutritional education in obese patients.
6. Other Lines
◦ Cost-effectiveness of genetic testing in paraganglioma-pheochromocytoma syndromes.
◦ Epidemiology of adrenal carcinoma.
